Recommendation 8

The expert panel suggests a strategy of screen with an HPV test followed by VIA and treat with cryotherapy (or LEEP when not eligible for cryotherapy) over a strategy of screen with cytology followed by colposcopy (with or without biopsy) and treat with cryotherapy (or LEEP when not eligible) (conditional recommendation, ⊕⊖⊖⊖ evidence)

Remarks: The benefits of the two screen-and-treat strategies are similar. However, there may be higher resources required in cytology programmes due to quality control, training, and waiting time. The addition of colposcopy requires a second visit. This recommendation applies to women regardless of HIV status.

Evidence-to-recommendation table

Decision domain	Judgement	Summary of reason for judgement
Quality of evidence *Is there high- or moderate-quality evidence?*	Yes ☐ / No ☒	There is low-quality evidence for the diagnostic test accuracy data for HPV test followed by VIA compared to cytology followed by colposcopy. There is low- to very-low-quality evidence for the effects of treatment and the natural progression of CIN from observational studies often with inconsistent results across studies. The link between test accuracy data and treatment effects is very uncertain.
Balance of benefits versus harms and burdens *Are you confident that the benefits outweigh the harms and burdens for the recommended strategy?*	Yes ☐ / No ☒	The benefits and harms of HPV test followed by VIA and cytology followed by colposcopy may be similar. However, there may be slightly fewer cancers detected with HPV test followed by VIA.
Values and preferences *Are you confident about the assumed or identified relative values and are they similar across the target population?*	Yes ☒ / No ☐	High value was placed on a screen-and-treat strategy versus no screening, since qualitative studies have shown that once women decide to be screened they find the screening tests and immediate treatment acceptable. High value was placed on the resources required.
Resource implications *Is the cost small relative to the net benefits for the recommended strategy?*	Yes ☒ / No ☐	Fewer resources may be required for HPV test followed by VIA as there may be additional resources required in cytology programmes due to increased training of providers, quality control, and waiting time. Colposcopy following cytology also requires a second visit.

Evidence for an HPV test followed by VIA compared to cytology followed by colposcopy to screen for CIN2+ in women of HIV-positive status

1. Flowchart of screen-and-treat strategies



* Outcomes are: mortality from cervical cancer, rate of cervical cancer detection, rate of CIN2+ detection, major bleeding, premature delivery, infertility, STI detection, major infections, and minor infections

2. Evidence used for decision-making: HPV test followed by VIA compared to cytology (ASCUS) and colposcopic impression

Diagnostic test accuracy (data based on women with unknown HIV status)

Pooled sensitivity HPV test	94% (95% CI: 89 to 97)	Pooled sensitivity VIA	69% (95% CI: 54 to 81)
Pooled specificity HPV test	90% (95% CI: 86 to 93)	Pooled specificity VIA	87% (95% CI: 79 to 92)
Pooled sensitivity cytology (ASCUS)	70% (95% CI: 57 to 81)	Pooled sensitivity colposcopic impression	95% (95% CI: 86 to 98)
Pooled specificity cytology (ASCUS)	95% (95% CI: 92 to 97)	Pooled specificity colposcopic impression	42% (95% CI: 26 to 61)

(Reference standard: colposcopy with biopsy when indicated)

2.1 Diagnostic test accuracy (DTA) evidence profile: HPV test followed by VIA compared to cytology (ASCUS) and colposcopic impression

Outcome	No. of studies (No. of patients)[a]	Study design	Factors that may decrease quality of evidence					DTA QoE	Effect per 1000 patients/year for pretest probability of 10%		Importance
			Limitations	Indirectness	Inconsistency	Imprecision	Publication bias		HPV test followed by VIA	Cytology followed by colposcopic impression	
True positives (patients with CIN2+)	14 studies (34 584 patients)	Cross-sectional and cohort studies	Serious[b]	None[c]	Serious[d]	None[e]	Undetected	⊕⊕⊖⊖ low	65	67	CRITICAL
TP absolute difference									2 fewer		
True negatives (patients without CIN2+)	14 studies (34 584 patients)	Cross-sectional and cohort studies	Serious[b]	None[c]	Serious[d]	None[e]	Undetected	⊕⊕⊖⊖ low	888	874	CRITICAL
TN absolute difference									14 more		
False positives (patients incorrectly classified as having CIN2+)	14 studies (34 584 patients)	Cross-sectional and cohort studies	Serious[b]	None[c]	Serious[d]	None[e]	Undetected	⊕⊕⊖⊖ low	12	26	CRITICAL
FP absolute difference									14 fewer		
False negatives (patients incorrectly classified as not having CIN2+)	14 studies (34 584 patients)	Cross-sectional and cohort studies	Serious[b]	None[c]	Serious[d]	None[e]	Undetected	⊕⊕⊖⊖ low	35	34	CRITICAL
FN absolute difference									1 more		

Footnotes:

[a] This is the number of studies that assessed DTA data for: 1. HPV test and VIA, and 2. HPV test and cytology.

[b] We used QUADAS to assess risk of bias. Half of studies only performed one biopsy of an abnormal lesion and had unclear blinding of tests. Colposcopy studies had unclear blinding of index test results. This was downgraded one level in the context of other factors, in particular indirectness.

[c] Data for HPV test followed by VIA and cytology followed by colposcopy were calculated based on sensitivity and specificity of the two tests. Direct data were not available. Diagnostic test accuracy data were based on women of unknown HIV status; the data were not considered indirect and so the quality of evidence was not downgraded.

[d] Estimates of HPV test, VIA, cytology (ASCUS) and colposcopy sensitivity/specificity were variable despite similar cut-off values; inconsistency was not explained by quality of studies. This was downgraded one level in the context of other factors, in particular imprecision.

[e] Wide CI for sensitivity and specificity of HPV test followed by VIA and cytology followed by colposcopy and therefore wide CI for TP, TN, FP, FN, may lead to different decisions depending on which confidence limits are assumed.

2.2 GRADE evidence table for patient-important outcomes following different screen-and-treat strategies: HPV test followed by VIA compared to cytology (ASCUS) and colposcopic impression

Outcomes	Events in the screen-and-treat strategies for patient-important outcomes (numbers presented per 1 000 000 patients)						
	HPV→VIA +/– CKC	HPV→VIA +/– LEEP	HPV→VIA +/– cryo	Cyto→colp imp +/– CKC	Cyto→colp imp +/– LEEP	Cyto→colp imp +/– cryo	No screen[10]
Mortality from cervical cancer[1]	1594	1691	1691	1524	1624	1624	4350
Cervical cancer incidence[2]	2231	2367	2367	2134	1752	2273	6075
CIN2+ recurrence[3]	29 393	31 404	31 404	28 124	30 186	30 186	79 575
Undetected CIN2+ (FN)	35 000			34 000			–
Major bleeding[4]	657	173	26	795	209	31	0
Premature delivery[5]	612	539	558	592	533	548	500
Infertility[6]	–	–	–	–	–	–	–
Major infections[7]	82	118	13	68	98	10	0
Minor infections[8]	867	558	599	717	461	496	0
Unnecessarily treated (FP)	12 000			26 000			–
Cancer found at first-time screening[9]	3168			4794			0

Footnotes:

The colours in the table: In each GRADE evidence table, colour-coding is used to highlight the 'desirability' of the effects for that outcome relative to other outcomes. The continuum runs from dark gray (desirable) through light gray and light pink to dark pink (least desirable).

The numbers in the table are based on

- CIN2+ pretest probability 10% in women of HIV-positive status (Denny et al., 2008; De Vuyst et al., 2012; Joshi et al., 2012; Zhang et al., 2012)
- VIA: Pooled sensitivity 69% (95% CI: 54 to 81), pooled specificity 87% (95% CI: 79 to 92)
- Cytology (ASCUS): Pooled sensitivity 70% (95% CI: 57 to 81), pooled specificity 95% (95% CI: 92 to 97)
- Colposcopy: Pooled sensitivity 95% (95% CI: 86 to 98), pooled specificity 42% (95% CI: 26 to 61)
- The overall QoE for each of these outcomes is very low ⊕⊖⊖⊖. Our lack of confidence in these effect estimates stems mainly from very low quality evidence for treatment effects and natural progression/history data

[1] We assume no mortality from cervical cancer in TN and FP. To calculate the mortality from cervical cancer in women of HIV-positive status, we assumed the same risk of mortality in women of unknown HIV status: 250 deaths per 350 women with cervical cancer. These numbers are based on Eastern Africa age-standardized rates of cervical cancer and mortality provided by WHO (http://globocan.iarc.fr/, accessed 30 October 2012).

[2] We assume no cervical cancer in TN or FP. The calculations for cervical cancer incidence in women of HIV-positive status with persistent CIN2+ are based on a 2.7 standardized Risk Ratio of cancer when compared to women with unknown HIV status (De Vuyst et al., 2008). For women of unknown status, we assumed 350 cervical cancers per 14 000 women who have persistent CIN2+ (i.e. FN). This incidence is based on Eastern Africa age-standardized rate of cervical cancer of 350 cervical cancers per 1 000 000 women, of whom 2% have CIN2+ (20 000 women with CIN2+, and a subsequent 30% regression for a total of 14 000 with persistent CIN2+). These data are available from WHO (http://globocan.iarc.fr/, accessed 30 October 2012).

[3] We assume no CIN2+ in TN and FP. Our calculations in the model are based on 90% natural persistence of CIN2+ with no treatment (10% regression) in FN. TP are treated and recurrence rates of CIN2+ are 5.3% in cryotherapy and LEEP, and 2.2% in CKC.

[4] We assumed major bleed would be 0 in TN and FN as they were not treated. We assumed 0.000339 of the population treated with cryotherapy, 0.002257 with LEEP, and 0.001705 with CKC, based on pooled proportions in observational studies with no independent controls, will have major bleeding.

[5] We assumed 5% population risk of premature delivery in 1% of women who become pregnant. Based on pooled meta-analysis of controlled observational studies, 0.001125 of the population treated with cryotherapy, 0.000925 with LEEP, and 0.001705 of the population treated with CKC will have premature delivery.

[6] We did not identify any data about the risk of infertility after treatment for CIN2+.

[7] We assumed major infection would be 0 in TN and FN as they were not treated. Based on pooled proportions from studies with no independent control, 0.000135 of the population treated with cryotherapy, 0.001279 with LEEP, and 0.000888 with CKC will have major infection.

[8] We assumed minor infection would be 0 in TN and FN as they were not treated. Based on pooled proportions from studies with no independent control, 0.006473 of the population treated with cryotherapy, 0.006027 with LEEP, and 0.009368 with CKC will have minor infection.

[9] Cancers detected at first-time screening calculated from Sankaranarayanan et al. (2005). Numbers for single screening tests were calculated as 'screen-detected' cancers in women who participated in the screening programme; and numbers for test with colposcopy were calculated as 'screen-detected' plus 'clinically detected' cancers. For a sequence of tests (e.g. HPV test followed by VIA), the greater number of cancers detected between tests was used. No cancers would be found in the 'no screen' group. This is not the annual incidence of cervical cancer (which is shown in a row above). It represents the cumulative rate of cancer development before screening started (i.e. the prevalence of cancer at the time when screening is first conducted).

[10] 'No screen' numbers were calculated using the same assumptions above for FN, with the exception of premature delivery which was baseline risk in the population.

3. Evidence used for decision-making: HPV test followed by VIA compared to cytology (ASCUS) and colposcopic impression and biopsy when indicated

Diagnostic test accuracy (data based on women with unknown HIV status)

Pooled sensitivity HPV test	94% (95% CI: 89 to 97)	Pooled sensitivity VIA	69% (95% CI: 54 to 81)	Pooled sensitivity cytology (ASCUS)	70% (95% CI: 57 to 81)
Pooled specificity HPV test	90% (95% CI: 86 to 93)	Pooled specificity VIA	87% (95% CI: 79 to 92)	Pooled specificity cytology (ASCUS)	95% (95% CI: 92 to 97)

(Reference standard: colposcopy with biopsy when indicated)

3.1 Diagnostic test accuracy (DTA) evidence profile: HPV test followed by VIA compared to cytology (ASCUS) and colposcopy with biopsy when indicated

Outcome	No. of studies (No. of patients)[a]	Study design	Factors that may decrease quality of evidence					DTA QoE	Effect per 1000 patients/year for pretest probability of 10%		Importance
			Limitations	Indirectness	Inconsistency	Imprecision	Publication bias		HPV test followed by VIA	Cytology followed by colposcopy with biopsy	
True positives (patients with CIN2+)	14 studies (34 584 patients)	Cross-sectional and cohort studies	Serious[b]	None[c]	Serious[d]	None[e]	Undetected	⊕⊕⊖⊖ low	65	70	CRITICAL
TP absolute difference									5 fewer		
True negatives (patients without CIN2+)	14 studies (34 584 patients)	Cross-sectional and cohort studies	Serious[b]	None[c]	Serious[d]	None[e]	Undetected	⊕⊕⊖⊖ low	888	900	CRITICAL
TN absolute difference									12 fewer		
False positives (patients incorrectly classified as having CIN2+)	14 studies (34 584 patients)	Cross-sectional and cohort studies	Serious[b]	None[c]	Serious[d]	None[e]	Undetected	⊕⊕⊖⊖ low	12	0	CRITICAL
FP absolute difference									12 more		
False negatives (patients incorrectly classified as not having CIN2+)	14 studies (34 584 patients)	Cross-sectional and cohort studies	Serious[b]	None[c]	Serious[d]	None[e]	Undetected	⊕⊕⊖⊖ low	35	30	CRITICAL
FN absolute difference									5 more		

Footnotes:

[a] This is the number of studies that assessed DTA data for: 1. HPV test and VIA, and 2. HPV test and cytology.

[b] We used QUADAS to assess risk of bias. Half of studies only performed one biopsy of an abnormal lesion and had unclear blinding of tests. This was downgraded one level in the context of other factors, in particular indirectness.

[c] Data for HPV test followed by VIA and cytology followed by colposcopy +/– biopsy were calculated based on sensitivity and specificity of the two tests. Direct data were not available. Diagnostic test accuracy data were based on women of unknown HIV status; the data were not considered indirect and so the quality of evidence was not downgraded.

[d] Estimates of HPV test, VIA and cytology (ASCUS) sensitivity/specificity were variable despite similar cut-off values; inconsistency was not explained by quality of studies. This was downgraded one level in the context of other factors, in particular imprecision.

[e] Wide CI for sensitivity and specificity of HPV test followed by VIA and cytology followed by colposcopy and therefore wide CI for TP, TN, FP, FN, may lead to different decisions depending on which confidence limits are assumed.

3.2 GRADE evidence table for patient-important outcomes following different screen-and-treat strategies: HPV test followed by VIA and cytology (ASCUS) and colposcopy with biopsy when indicated

Outcomes	Events in the screen-and-treat strategies for patient-important outcomes (numbers presented per 1 000 000 patients)						
	HPV→VIA +/– CKC	HPV→VIA +/– LEEP	HPV→VIA +/– cryo	Cyto→colp biopsy +/– CKC	Cyto→colp biopsy +/–LEEP	Cyto→colp biopsy +/– cryo	No screen[10]
Mortality from cervical cancer[1]	1594	1691	1691	1376	1481	1481	4350
Cervical cancer incidence[2]	2231	2367	2367	1926	2073	2073	6075
CIN2+ recurrence[3]	29 393	31 404	31 404	25 416	27 586	27 586	79 575
Undetected CIN2+ (FN)	35 000			30 000			–
Major bleeding[4]	657	173	26	601	158	24	0
Premature delivery[5]	612	539	558	584	530	544	500
Infertility[6]	–	–	–	–	–	–	–
Major infections[7]	82	118	13	62	90	9	0
Minor infections[8]	867	558	599	656	422	453	0
Unnecessarily treated (FP)	12 000			0			–
Cancer found at first-time screening[9]	3168			3545			0

Footnotes:

The colours in the table: In each GRADE evidence table, colour-coding is used to highlight the 'desirability' of the effects for that outcome relative to other outcomes. The continuum runs from dark gray (desirable) through light gray and light pink to dark pink (least desirable).

The numbers in the table are based on

- CIN2+ pretest probability 10% in women of HIV-positive status (Denny et al., 2008; De Vuyst et al., 2012; Joshi et al., 2012; Zhang et al., 2012)
- HPV test: Pooled sensitivity94% (95% CI: 89 to 97), pooled specificity 90% (95% CI: 86 to 93)
- VIA: Pooled sensitivity 69% (95% CI: 54 to 81), pooled specificity 87% (95% CI: 79 to 92)
- Cytology (ASCUS): Pooled sensitivity 70% (95% CI: 57 to 81), pooled specificity 95% (95% CI: 92 to 97)
- The overall QoE for each of these outcomes is very low ⊕⊝⊝⊝. Our lack of confidence in these effect estimates stems mainly from very-low-quality evidence for treatment effects and natural progression/history data.

[1] We assume no mortality from cervical cancer in TN and FP. To calculate the mortality from cervical cancer in women of HIV-positive status, we assumed the same risk of mortality in women of unknown HIV status: 250 deaths per 350 women with cervical cancer. These numbers are based on Eastern Africa age-standardized rates of cervical cancer and mortality provided by WHO (http://globocan.iarc.fr/, accessed 30 October 2012).

[2] We assume no cervical cancer in TN or FP. The calculations for cervical cancer incidence in women of HIV-positive status with persistent CIN2+ are based on a 2.7 standardized Risk Ratio of cancer when compared to women with unknown HIV status (De Vuyst et al., 2008). For women of unknown status, we assumed 350 cervical cancers per 14 000 women who have persistent CIN2+ (i.e. FN). This incidence is based on Eastern Africa age-standardized rate of cervical cancer of 350 cervical cancers per 1 000 000 women, of whom 2% have CIN2+ (20 000 women with CIN2+, and a subsequent 30% regression for a total of 14 000 with persistent CIN2+). These data are available from WHO (http://globocan.iarc.fr/, accessed 30 October 2012).

[3] We assume no CIN2+ in TN and FP. Our calculations in the model are based on 90% natural persistence of CIN2+ with no treatment (10% regression) in FN. TP are treated and recurrence rates of CIN2+ are 5.3% in cryotherapy and LEEP, and 2.2% in CKC.

[4] We assumed major bleed would be 0 in TN and FN as they were not treated. We assumed 0.000339 of the population treated with cryotherapy, 0.002257 with LEEP, and 0.001705 with CKC, based on pooled proportions in observational studies with no independent controls, will have major bleeding.

[5] We assumed 5% population risk of premature delivery in 1% of women who become pregnant. Based on pooled meta-analysis of controlled observational studies, 0.001125 of the population treated with cryotherapy, 0.000925 with LEEP, and 0.001705 of the population treated with CKC will have premature delivery.

[6] We did not identify any data about the risk of infertility after treatment for CIN2+.

[7] We assumed major infection would be 0 in TN and FN as they were not treated. Based on pooled proportions from studies with no independent control, 0.000135 of the population treated with cryotherapy, 0.001279 with LEEP, and 0.000888 with CKC will have major infection.

[8] We assumed minor infection would be 0 in TN and FN as they were not treated. Based on pooled proportions from studies with no independent control, 0.006473 of the population treated with cryotherapy, 0.006027 with LEEP, and 0.009368 with CKC will have minor infection.

[9] Cancers detected at first-time screening calculated from Sankaranarayanan et al. (2005). Numbers for single screening tests were calculated as 'screen-detected' cancers in women who participated in the screening programme; and numbers for test with colposcopy were calculated as 'screen-detected' plus 'clinically detected' cancers. For a sequence of tests (e.g. HPV test followed by VIA), the greater number of cancers detected between tests was used. No cancers would be found in the 'no screen' group. This is not the annual incidence of cervical cancer (which is shown in a row above). It represents the cumulative rate of cancer development before screening started (i.e. the prevalence of cancer at the time when screening is first conducted).

[10] 'No screen' numbers were calculated using the same assumptions above for FN, with the exception of premature delivery which was baseline risk in the population.

4. References

4.1 References to studies included in meta-analysis of diagnostic test accuracy

Agorastos T et al. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecologic Oncology, 2005, 96(3):714–720.

Belinson J et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecologic Oncology, 2001, 83(2):439–444.

Bigras G, De Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: Results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13 842 women. British Journal of Cancer, 2005, 93(5):575–581.

Cardenas-Turanzas M et al. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. Cancer Epidemiology Biomarkers and Prevention, 2008, 17(10):2865–2871.

de Cremoux P et al. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. American Journal of Clinical Pathology, 2003, 120(4):492–499.

Depuydt CE et al. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiology Biomarkers and Prevention, 2011, 20(4):628–637.

De Vuyst H et al. Comparison of Pap smear, visual inspection with acetic acid, human papillomavirus DNA–PCR testing and cervicography. International Journal of Gynecology & Obstetrics, 2005, 89(2):120–126.Hovland S et al. A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo. British Journal of Cancer, 2010, 102(6):957–965.

Mahmud SM et al. Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo. Gynecologic Oncology, 2012, 124(2):286–291.

Monsonego J et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. International Journal of Cancer, 2011, 129(3):691–701.

Pan Q et al. A thin-layer, liquid-based Pap test for mass screening in an area of China with a high incidence of cervical carcinoma: a cross-sectional, comparative study. Acta Cytologica, 2003, 47(1):45–50.

Petry KU et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. British Journal of Cancer, 2003, 88(10):1570–1577.

Qiao YL et al. A new HPV–DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncology, 2008, 9(10):929–936.

Shastri SS et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bulletin of the World Health Organization, 2005, 83(3):186–194.

Sodhani P et al. Test characteristics of various screening modalities for cervical cancer: a feasibility study to develop an alternative strategy for resource-limited settings. Cytopathology, 2006, 17(6):348–352.

4.2 References to studies included for diagnostic test accuracy of colposcopic impression

Belinson J et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecologic Oncology, 2001, 83(2):439–444.

Cantor SB et al. Accuracy of colposcopy in the diagnostic setting compared with the screening setting. Obstetrics & Gynecology, 2008, 111(1):7–14.

Cremer ML et al. Digital assessment of the reproductive tract versus colposcopy for directing biopsies in women with abnormal Pap smears. Journal of Lower Genital Tract Disease, 2010, 14(1):5–10.

Cristoforoni PM et al. Computerized colposcopy: results of a pilot study and analysis of its clinical relevance. Obstetrics & Gynecology, 1995, 85(6):1011–1016.

Durdi GS et al. Correlation of colposcopy using Reid colposcopic index with histopathology – a prospective study. Journal of the Turkish German Gynecology Association, 2009, 10(4):205–207.

Ferris DG, Miller MD. Colposcopic accuracy in a residency training program: defining competency and proficiency. Journal of Family Practice, 1993, 36(5):515–520.

Homesley HD, Jobson VW, Reish RL. Use of colposcopically directed, four-quadrant cervical biopsy by the colposcopy trainee. Journal of Reproductive Medicine, 1984, 29(5):311–316.

Jones DE et al. Evaluation of the atypical Pap smear. American Journal of Obstetrics & Gynecology, 1987, 157(3):544–549.

Kierkegaard O et al. Diagnostic accuracy of cytology and colposcopy in cervical squamous intraepithelial lesions. Acta Obstetricia et Gynecologica Scandinavica, 1994, 73(8):648–651.

Mousavi AS et al. A prospective study to evaluate the correlation between Reid colposcopic index impression and biopsy histology. Journal of Lower Genital Tract Disease, 2007, 11(3):147–150.

Patil K et al. Comparison of diagnostic efficacy of visual inspection of cervix with acetic acid and Pap smear for prevention of cervical cancer: is VIA superseding Pap smear? Journal of SAFOG, 2011, 3(3):131–134.

4.3 Additional references

Denny L et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstetrics & Gynecology, 2008, 111(6):1380–1387.

De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. European Journal of Cancer Prevention, 2008, 17(6):545–554.

De Vuyst H et al. Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. British Journal of Cancer, 2012, 107(9):1624–1630.

Joshi S et al. Screening of cervical neoplasia in HIV-infected women in Maharashtra, India. AIDS, 2013, 27(4):607–615.

Sankaranarayanan R et al.; Osmanabad District Cervical Screening Study Group. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. International Journal of Cancer, 2005, 116(4):617–623.

Zhang HY et al. HPV prevalence and cervical intraepithelial neoplasia among HIV-infected women in Yunnan Province, China: a pilot study. Asian Pacific Journal of Cancer Prevention, 2012, 13(1):91–96..